local_hospital

Suomen Terveystalo Oy

Address
lock Available on a paid plan

Psychiatry and Psychology and Mental Disorders

At Suomen Terveystalo Oy in Helsinki, clinical trials in mental health focus on major depressive disorder, generalized anxiety disorder, and related symptoms such as anhedonia. The studies are designed to test new treatment options and assess whether they can improve mood, anxiety, and daily functioning in people who have not responded well to current care.

  • Research on adjunctive and stand-alone approaches for major depressive disorder
  • Studies targeting generalized anxiety disorder and persistent anxiety symptoms
  • Trials evaluating whether new therapies can improve depressive symptoms and overall well-being

These trials reflect a strong interest in finding better options for common and often hard-to-treat psychiatric conditions.

Nervous System Diseases

The site also conducts research in neurology, with studies involving migraine, narcolepsy, and mild to moderate Alzheimer’s disease. The main goals include preventing migraine attacks, reducing daytime sleepiness, and improving thinking skills and global function in people with cognitive decline.

  • Trials for migraine prevention and acute relief in adults and children
  • Studies in narcolepsy and narcolepsy with cataplexy aimed at managing excessive sleepiness
  • Research in Alzheimer’s disease focused on cognition and daily functioning

These investigations support the development of more effective therapies for neurological disorders that can significantly affect quality of life.

Cardiovascular Diseases

Clinical trial activity in cardiovascular diseases includes work on heart failure, hypertension, and broader cardiovascular disease risk in people with metabolic conditions. The research is aimed at improving outcomes, lowering the risk of serious heart events, and testing new treatment combinations for patients with complex disease profiles.

  • Studies in heart failure with preserved or mildly reduced ejection fraction and obesity
  • Trials in type 2 diabetes, hypertension, and established cardiovascular disease
  • Research evaluating whether new therapies can reduce hospitalizations and cardiovascular deaths

These trials highlight a focus on better long-term care for patients with overlapping heart and metabolic conditions.

Respiratory Tract Diseases

In the area of respiratory tract diseases, the site is involved in studies on chronic obstructive pulmonary disease and related cardiopulmonary outcomes. The purpose of this research is to determine whether new treatment combinations can improve breathing-related health and reduce serious complications.

  • Trials in COPD examining symptom control and overall respiratory outcomes
  • Research linking lung disease treatment with broader cardiopulmonary benefits
  • Studies designed to evaluate the effectiveness of new inhaled and combined therapies

This work supports efforts to improve both daily respiratory symptoms and longer-term disease control.

Digestive System Diseases

Research in digestive system diseases centers on celiac disease, with trials exploring ways to reduce gluten-related intestinal injury and improve disease management. The main objective is to test new therapies that may protect the gut and offer better control of symptoms and inflammation.

  • Studies in celiac disease focused on reducing gluten-induced intestinal damage
  • Research aimed at improving treatment options for people living with ongoing dietary sensitivity
  • Clinical testing of approaches intended to support safer and more effective disease control

This area adds an important digestive health dimension to the broader clinical research portfolio at the site.

Site Overview

assignment
2
connected trials
corporate_fare
3
sponsors
science
3
IMPs

Activity Indicator

Last 6 months

0
Trials started
-100% vs previous period.
1
Trials started 6–12 months ago
2
Total trials linked
Moderately Active
trending_downDeclining-100%
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status
lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years
lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
1
Sponsors (total)
3
Active sponsors
2

Sponsor Network

Top 2 by active trials.

lock +1 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

No repeated partnerships found.

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 107 other sites in Finland

description
Trial volume
2
Outperforms 32% of sites
public
Therapeutic diversity
2areas
Outperforms 36% of sites
groups
Sponsor diversity
3sponsors
Outperforms 56% of sites

Therapeutic Area Benchmark — Finland

Select a therapeutic area to compare against other sites in Finland.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Finland

Market Share

Country: Finland

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Suomen Terveystalo Oy

lock Showing 1 of 2 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
Efficacy and Safety of Aticaprant as Adjunctive Therapy in Adults with Major Depressive Disorder and Anhedonia Unresponsive to AntidepressantsJanssen Cilag InternationalPhase IIINot RecruitingNov 2024Feb 2025

IMP list

lock Showing 1 of 3 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Aticaprant1Unknown2024-11-142024-11-14

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.